WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SB 317

Overview

SB 317 (Utah, 2026) – Opioid Terminology Amendments is a bill focused on updating terminology related to opioids and opioid-related activities across the Utah Code. The changes are largely definitional and conforming, aligning terms like “opiate” with “opioid” and updating related cross-references. The bill also enhances overdose response infrastructure and reporting related to opioids, with several provisions creating or modifying programs, immunities, and guidelines to support treatment, prevention, and public health data collection. No new money is appropriated in this bill.

Purpose and Intent

  • Improve clarity and consistency in terminology related to opioids across statutes.
  • Modernize references from “opiate” and related terms to current nomenclature (e.g., “opioid,” “opioid antagonist,” “opioid-related drug overdose event”).
  • Expand and formalize opioid overdose response, treatment access, and prevention activities.
  • Establish reporting, training, and programmatic structures to address opioid misuse and overdose in Utah.

Key Provisions and Changes

  • Definitions and Terminology (Sections 1, 3, 4, 15, 17, 18):

    • Change defined term “opiate” to “opioid-like substance” or “opioid antagonist” where appropriate.
    • Replace “opiate” with “opioid-like substance” in descriptions of certain controlled substances.
    • Adopt “opioid-related drug overdose event” in place of “opiate-related” terms.
    • Define related terms consistently (e.g., “overdose outreach provider,” “opioid antagonist,” “coprescribe,” “self-administered hormonal contraceptive,” etc.).

  • County Jail Reporting and Oversight (Section 2):

    • Requires annual county jail reports to the State Commission on Criminal and Juvenile Justice, including:
    • Demographics, population, bookings, in-custody deaths, withdrawal treatment policies, and medication-assisted treatment (MAT) data.
    • Policies on withdrawal management, MAT, screening, and treatment for substance use disorders.
    • Allows data access under MOUs with protections for ongoing investigations; redaction of identifying information when compiling reports.
    • Annual compilation and distribution to relevant committees and advocacy agencies.

  • Opioid Overdose Treatment and Immunity (Sections 5–7):

    • Establishes immunities for administering an opioid antagonist (e.g., naloxone) by overdose outreach providers or other individuals acting in good faith.
    • Clarifies that health care providers retain liability protections only when acting within scope or with no duty to respond otherwise.
    • Requires education for recipients of an opioid antagonist and linkage to follow-up medical care.

  • Standing Orders and Dispensing (Sections 6–7):

    • Allows standing prescription drug orders for opioid antagonists to be dispensed without a separate prescription, under physician-approved protocols.
    • Requires record-keeping and annual review of dispensing practices by those authorized.

  • Opioid Overdose Outreach Pilot Program (Section 8):

    • Creates an “Opioid Overdose Outreach Pilot Program” within the Department.
    • Grants can fund purchase and training for opioid antagonists (limited use for training costs).
    • Establishes reporting requirements for grantees (usage, individuals served, lives saved, data handling).

  • Coprescribing Guidelines (Section 9):

    • Directs the Department to develop guidelines for controlled-substance prescribers to coprescribe opioid antagonists, in collaboration with licensing boards.

  • Public Education and Pamphlets (Section 10):

    • Requires development and distribution of pamphlets about opioid-like substances, their risks, storage/disposal, alternatives for pain management, naloxone access, and resources for substance use disorder treatment.
    • Ensures pamphlets are clear, periodically evaluated, and available in multiple languages.

  • Chronic Pain and Data Initiatives (Sections 11–12):

    • Duty to establish a program to reduce deaths/harm from prescription opioid-like substances used for chronic pain.
    • Emphasis on education, public awareness of the Utah Controlled Substance Database, and better management of chronic pain in relation to opioid use.

  • Other Administrative/Technical Provisions (multiple sections):

    • Updates to definitions and cross-references across the code.
    • Clarifies exemptions and scope for overdose-related activities under licensure and professional practice acts.

Who Is Affected

  • Individuals at risk of opioid overdose and their families or friends (through naloxone access and education).
  • Overdose outreach providers, health care providers, pharmacists, and other licensed professionals (liability protections and standing orders).
  • Law enforcement, corrections, and county jail systems (reporting requirements and data sharing).
  • Health departments, local substance use authorities, and state agencies (programs, pilot funding, and rulemaking).
  • Individuals with opioid use or chronic pain conditions (education, pilot program activities, and data-driven policy adjustments).

Procedural and Timeline Details

  • Effective dates: May 6, 2026, with several provisions aligning to existing renumbered/amended code sections.
  • Several sections reference conforming changes from prior Utah law (2023–2025 amendments) to ensure consistency.
  • Some components (e.g., syringe exchange in Section 12) create rules and reporting requirements but prohibit state funding for syringe exchange programs (with caveats about municipal/federal funding allowances).
  • Partially repealed provisions: existing sections are renumbered/amended, and some sections are set to be amended according to the 2025 Laws.

Potential Impact

  • Increased clarity and consistency in opioid-related terminology across statutes, reducing ambiguity.
  • Expanded access to naloxone and formalized overdose response, with liability protections for responders.
  • Strengthened data collection and reporting on jail-based opioid issues and overdose outcomes.
  • Enhanced public education on opioid risks, treatment options, and safe storage/disposal.
  • Creation of pilot programs and grant mechanisms to fund overdose prevention and treatment initiatives.
  • Broader framework for coordinating multi-agency efforts to address opioid misuse and overdose in Utah.

Note: This summary focuses on the bill’s substantive content, definitions, programmatic provisions, and potential impact based on the text provided.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.